

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61M 15/00	A1	(11) International Publication Number: WO 90/13328 (43) International Publication Date: 15 November 1990 (15.11.90)
(21) International Application Number: PCT/US90/02412		(74) Agents: SPRAGUE, Robert, W. et al.; Riker Laboratories, Inc., P.O. Box 33427, Saint Paul, MN 55133 (US).
(22) International Filing Date: 30 April 1990 (30.04.90)		
(30) Priority data: 8909891.7 28 April 1989 (28.04.89) GB		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent).
(71) Applicant: RIKER LABORATORIES, INC. [US/US]; P.O. Box 33427, Saint Paul, MN 55133 (US).		
(72) Inventors: HODSON, Peter, D. ; 5 Kingmead Avenue, Trowell Park, Trowell, Notts NG9 3QX (GB). SMITH, David, K. ; 8 Springfield Close, Loughborough, Leics LE11 EPT (US). WASS, Anthony, C., L. ; The Mousehole, Duddington, Stamford, Lincs PE9 3QE (US). VELASQUEZ, David, J. ; 4221 291st St. E., Randolph, MN 55065 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: DRY POWDER INHALATION DEVICE



(57) Abstract

A dry powder inhalation device comprising a housing (1) defining a chamber (3) in communication with a patient port (4) in the form of a mouthpiece or nasal adaptor (5), and an elongate carrier (8) bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier (8) may sequentially be exposed within the chamber (3), the device comprising one or more air inlets (2) such that when a patient inhales through the patient port (4) an air flow is established from the air inlet(s) (2) to the patient port (4) through the chamber (3) such that particles of the powdered medicament of respirable size from said exposed area of the elongate carrier (8) are entrained within the air flow. The elongate carrier conveniently comprises a tape having a surface releasably bearing micronised medicament. The tape may be mounted in a removable cassette in a similar manner to a magnetic tape cassette.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

Dry powder inhalation device.

This invention relates to a dry powder inhalation device and in particular to an inhalation device capable of dispensing a plurality of doses of medicament to a 5 patient. The invention also relates to an elongate carrier releasably supporting powdered medicament.

Asthma and other respiratory diseases have long been treated by the inhalation of appropriate medicament. For many years the two most widely used and convenient 10 choices of treatment have been the inhalation of medicament from a drug solution or suspension in a metered dose pressurised inhaler (MDI), or inhalation of powdered drug generally admixed with an excipient, from a dry powder inhaler (DPI). With growing concern being 15 voiced over the strong link between depletion of the earth's ozone layer and chlorofluorocarbon (CFC) emissions, the use of these materials in pressurised inhalers is being questioned and interest in DPI systems has been stimulated.

20 Existing single and multiple dose dry powder inhalers use either individual pre-measured doses or bulk powder reservoirs. In both cases only fairly large quantities (e.g. several hundred micrograms) can constitute a dose due to problems associated with 25 accurately transferring a measured small quantity of powder either into a capsule etc., or from a bulk reservoir within an inhaler. With potent drugs this introduces the necessity to add excipients, such as lactose powder, to increase the quantity of powder to be 30 measured. These excipients are undesirable, however, as they pose subsequent powder deagglomeration problems and cause dryness in the patient's mouth. In addition, the use of individual pre-measured doses tends to lead to the production of bulky inhalation devices.

Dry powder inhalers in which the medicament is introduced into the device from a capsule are disclosed in U.S. Patent Nos. 3,948,264, 3,971,377 and 4,147,166 5 and British Patent No. 1479283. Dry powder inhalers having a reservoir of dry powder from which unit doses are transferred to a chamber by means of a delivery system, such as a rotating perforated membrane in which the perforations are filled with powder from the 10 reservoir, are disclosed in British Patent Application Nos. 2102295 and 2144997 and European Patent Application Nos. 69715, 79478 and 166294.

U.S. Patent Nos. 4,735,358, European Patent Application No. 239802 and British Patent Application 15 Nos. 2108390, 2122903 and 2166957 disclose vaporisers in which active substances capable of modifying the local atmosphere e.g. insecticides, deodorants and aromatics are vaporised for dispersion to the atmosphere. The active substance is carried or impregnated on a belt or 20 tape consisting of a suitable base material, in such a state that vaporisation can be conducted at ambient temperature or under administration of localised heating by a vaporising head. The substance is maintained in an inactive condition until the belt passes over the 25 vaporising head whereby thermal release is achieved. The belt may be moved to the vaporising head by hand or at a fixed speed by a motor driving feed means through a reduction gear and is taken up by a shaft or spindle. In one embodiment the belt is contained in a cassette to 30 provide a re-usable device, the cassette being engaged by drive means and having a suitable aperture for the belt to pass across the vaporising head. None of the vaporisers disclosed are suitable for delivering a predetermined unit dose of powdered solid medicament to a 35 patient.

It has now been found that predetermined doses of a dry powder may be stored in and dispersed from an inhaler by means of a preloaded elongate carrier, such as a tape or cord.

Therefore according to the present invention there is provided a dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that particles of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow.

The invention provides a simple, effective dry powder inhaler which is capable of delivering multiple, uniform doses of a medicament to a patient. The device is simple to operate and does not require the patient to insert capsules of medicament or rely upon a separate reservoir of medicament in order to load the device for use. The medicament is generally preloaded on an elongate carrier, sections of which are sequentially exposed in the chamber for dispensing the medicament. The elongate carrier may be conveniently loaded on a spool (in a similar manner to a photographic film) or in a cassette (in a similar manner to an audio cassette). The elongate carrier may have any ratio of length : width but is generally greater than 5 : 1, usually greater than 10 : 1 preferably between 100 : 1 and 1000 : 1.

The preloaded elongate carrier can take a variety of forms, but preferably is a tape, web, belt or cord. The powdered medicament may be retained on the carrier by electrostatic attraction, van der Waals forces, physical attraction, mechanical binding, wedging or by a cover layer or an overlying layer of the same carrier when the

carrier is wound etc. One or more surfaces of the carrier and optionally the interior of the carrier may be configured to assist in retaining the particles of powder.

- 5 The carrier may be constructed from one or more of a wide range of natural and synthetic materials e.g. polyethylene, polypropylene, polyester, polytetrafluoroethylene or a co-polymer thereof and
- 10 cellulose. The materials may be in the form of non-woven fibrous materials, loose weave materials or fabrics, materials having a surface pile, films, microporous materials, microgrooved materials, cords of twisted fibres, or any material or composite of more than one
- 15 material having small surface grooves, recesses, interstices, apertures or embossed surface structures having a typical size of <500 µm in either depth or height and of greater than 0.1 µm in at least one other dimension in order to retain the particles of powder.
- 20 A microgrooved material preferably comprises a tape, web or belt with one or more grooves of width 10 to 500 µm at the carrier surface and a depth of 10 to 500 µm, but the grooves may generally have dimensions at least an order of magnitude larger than the largest
- 25 particle. The microgrooves may be filled partially, or completely, the latter facilitating a means of dosage control if the material is loaded under uniform conditions. The microgrooves need not be continuous or straight and may run in one or two dimensions.
- 30 A microporous material preferably comprises a tape, web or belt having pores of diameter 0.1 to 100 µm which may be randomly orientated. At least a portion of the pores must be on the exterior surface. A preferred method of pore formation utilises solvent extraction of
- 35 oil droplets dispersed in a film of carrier material.

A further embodiment of a microporous material is produced by a laser drilling process and comprises a tape, web or belt having pores of diameter 1 to 100 µm, preferably 20 to 50 µm, in at least one surface.

A non-woven material may be of any suitable format, but is preferably in the form of a tape, web or belt. It may contain any type and form of fibres, although fibres 5 of 0.1 μm to 100 μm diameter are preferred and most preferably 5 to 20 μm diameter. Fibres may be of any appropriate length but preferably 1 to 100 mm. Formation of the non-woven material may be any suitable method, for example, combing or carding, deposition of fibres from a 10 transport gas or fluid, or the extrusion and blowing of microfibres. Bonding, e.g. by thermal fusion, of the fibres over at least part of the area of the material may be carried out to increase the mechanical strength of the material. Such bonding may be most conveniently situated 15 at the edges of the tape or web and may be conveniently formed as part of a process of slitting the tape, e.g., by a thermal or laser slitting means. The material may also be perforated or embossed and may optionally be air permeable.

20 The non-woven material may use a mixture of fibre compositions or forms. In one preferred embodiment, bicomponent fibres, with a readily-fusible outer component, are used. Such fibres are capable of ready inter-bonding to prevent, or minimise fibre shedding. In 25 another preferred embodiment, spun-bonded fibres are used to achieve the same objective by taking advantage of their longer fibre length. In a third embodiment, continuous reinforcing filaments may lie in the plane of the material, so providing fibre anchorage and conferring additional mechanical strength to the material. In a 30 fourth embodiment, paper type non-woven materials formed by deposition of fibres from a liquid may be used, as they may possess additional strength compared to other materials and may lead to reduced fibre shedding, due to 35 increased fibre entanglement.

The tape, web or belt may contain reinforcing threads in the plane of the material and/or a backing layer e.g. a metal foil such as aluminium, or a polymer film or a combination thereof. A metallized backing layer is advantageous when the carrier is stored as a roll because it imparts a conducting surface, which may reduce transfer of medicament from the coated surface to the uncoated surfaces. The backing layer may have perforations to allow for passage of an airflow through the carrier material proper.

The carrier may be loaded by the brushing, scraping or smearing of powdered medicament onto the carrier surface.

Alternatively the carrier may be loaded by evaporation from a suspension of medicament, by precipitation from a solution of medicament or by deposition from an aerosol for example by spraying, impaction, impingement, diffusion or by electrostatic or van der Waals attractions. For example, the medicament particles may be given an intentional electrical charge immediately prior to loading. The technique of charged aerosol deposition may be complimented by the use of a carrier with an inherent electrostatic charge. Ideally, the carrier should be an insulator such as polytetrafluoroethylene capable of retaining the charge, alternatively the carrier may contain an artificial charge due to the presence of electrets. Generally, the choice of loading technique will be governed by the properties of the carrier material employed.

Masks stencils etc. may be employed during coating, in order to allow the coating of discrete areas of carrier medium with individual doses. Patterned deposition of the medicament may be used to prevent contact between drug and any ink markings on tape.

A preferred carrier for use in this invention is disclosed and claimed in U.S. Patent Application Number, Attorney Docket FN 45128 USA 1A, of even date

5 incorporated herein by reference. That Patent Application discloses a flexible sheet material comprising a plurality of discrete depressions in at least one surface thereof, each of the depressions having a depth of about 5 to 500 μm , but less than the thickness
10 of the sheet material, and an opening at the surface of the sheet material of about 10 to 500 μm across, a substantial number of the depressions being at least partially filled, preferably at least 75% filled, with micronised medicament, and the area of the surface of the
15 sheet material between the depressions being substantially free of micronised medicament.

The flexible sheet material may comprise a substantially regular array of depressions or microdimples formed in the top surface of a layer of
20 polymeric material. The depressions are generally truncated cones, but may alternatively be of any suitable configuration for holding micronised medicament including generally truncated pyramids, partial hemispheres and tetrahedrons and other geometric configurations, as well
25 as non-geometrical configurations. Presently preferred depressions have a sidewall angle of about 15 to 20° to the vertical. The array of depressions may take any form or pattern and need not be regular (i.e., the array may be irregular in appearance).

30 The depressions generally have a depth of about 5 to 500 μm and an opening at the surface of the sheet material of about 10 to 500 μm across with respect to the major axis of the opening. In the case of the depressions having generally circular openings such as truncated
35 cones or partial hemispheres, for example, the major axis discussed above is, in fact, the diameter of the circular opening. Preferred depressions have a depth of about 5 to 150 μm and an opening (e.g., diameter in the case of truncated cones or partial hemispheres or the like) at

the surface of the sheet material of about 50 to 200 μm . The depressions generally will be spaced about 20 to 200 μm , preferably about 50 to 200 μm , from one another. Preferably the depressions will number from about 500 to 5 15,000 per cm^2 of the sheet material. The volume of each depression and the spacing or number of the depressions will depend upon the potency of the medicament and the area of the sheet material intended to represent a single dose of the medicament. Preferably, 10 the sheet material will have a substantially uniform depression volume per unit area.

The sheet material may further comprise a support layer, e.g., of paper. The layer of polymeric material may be laminated or melt-bonded to or extruded onto the 15 support layer. Other support layers may be formed of non-wovens or polymers such as polyester.

The layer of polymeric material may comprise any suitable polymer such as polyethylene, polypropylene, polyester, polytetrafluoroethylene and cellulose. 20 Polyethylene is preferred. The layer of polymeric material will be typically about 25 to 1000 μm in thickness.

The sheet material may be formed of a single material such as polypropylene. The support layer is not 25 required in such an embodiment since the sheet material even without the support layer will exhibit sufficient integrity and durability.

A preferred sheet material is prepared using polyethylene-coated kraft paper available from Schoeller 30 Company. The depressions have a depth such that they do not form pores extending through the entire thickness of the sheet material.

The top surface of the sheet material is generally coated with micronised drugs to at least partially fill 35 the depressions followed by general removal of excess drug from the top surface of the sheet material in the

areas of the top surface between the depressions, e.g., by scraping optionally followed by rolling between silicone pads, silicone having an affinity for the particles of drug.

- 5 As the packing density of the micronised medicament in the depressions may have influence on the form and amount of medicament released from the sheet material during the aerosolisation process, care should be taken to assure that the packing density remains substantially
10 uniform during the coating process.

The opening and depth dimensions and the spacing of the depressions influence how much micronised medicament the sheet material can carry per unit area for a given degree of compression of the medicament during loading or
15 coating. Further, depression depth may influence the degree to which medicament is released from the sheet material and its relative state of agglomeration or unagglomeration. Using albuterol sulfate with a mean particle size of 1.7 μm and for single impactions of
20 strength appropriate to an inhaler on areas of about 2 to 10 cm^2 of sheet material, the following was observed. The percentage of medicament retained on the sheet material or tape decreases as depression depth increases, this being about 95% at 14 μm , about 60% at 28 μm and about
25 35% at 45 μm . Further, the respirable fraction (i.e., the percentage of drug which is in particles of aerodynamic diameter of equal to or less than about 6.4 μm) similarly decreases as depression depth increases, this being about 65% at 14 μm , about 30% at 28 μm and about 10% at 37 μm .
30 These two trends result in the proportion of total medicament released in particles of respirable size remaining generally similar for the depression depths studied (this being about 5 to 15% of total medicament).

Depressions may be formed in the sheet material by
35 any suitable technique such as micro-imprinting using a photolithographically-patterned magnesium alloy plate or other micro-machined plate. Other conventional techniques which may be used are optical imaging or laser imaging.

As an illustrative example a sheet material has been prepared using a photolithographically produced etched magnesium alloy master plate having an array of pyramidal-shaped protuberances numbering about 1550 per 5 cm^2 wound about a steel roller. The roller was heated to about 225°F using oil. The polyethylene surface of polyethylene-coated kraft paper (commercially available from Schoeller Company) was pressed against the surface with a rubber or steel nip roll, also heated with oil and 10 hydraulically pressurised against the patterned roll.

It is preferred that the medicament employed exhibit a potency which permits a single dose to be loaded onto the sheet material in an area of less than about 25 cm^2 and preferably less than about 5 cm^2 . More preferred is a 15 sheet material containing a drug in such a manner and of such a type that between 0.25 and 2.25 cm^2 , most preferably between 0.5 and 2.0 cm^2 , of the sheet material will contain a single dose. Stated differently, given that a sheet material of the invention may conveniently 20 carry between about 10 and 150 μg of medicament per cm^2 , the potency of the medicament will preferably be such that a single dose may be carried on the above stated 0.25 to 2.25 cm^2 of sheet material.

The format of the carrier in the most preferred 25 embodiment is a tape. The nature of the carrier dictates the method of transport between storage means and the chamber where aerosolisation takes place. In a preferred embodiment, storage of preloaded carrier is effected by winding on a spool which is contained within 30 a cassette. Use of a tape web or belt allows other conformations to be imparted to the stored carrier by folding, for example, as a concertina conformation which has the advantage that the medicament bearing surfaces are in association and thereby prevent net transfer of 35 medicament during storage. Each fold may define a unit dose of medicament. Folding along the longitudinal axis of the tape, referred to as hybrid folding, may also reduce unwanted net transfer of medicament. Cord or string may conveniently be stored as a coil.

The device includes means for advancing the elongate carrier through the chamber to sequentially expose areas of the carrier for release of medicament during inhalation by the patient. The means for advancement may 5 take a variety of forms depending upon the type of elongate carrier and whether the exposed areas of carrier are to be retained within the device. For example, tapes webs and belts may include a series of apertures which are engaged by one or more sprocketed guide wheels or 10 rollers in a similar manner to a camera or printer. Alternatively, or in addition, the carrier may be wound on a take-up spool, rotation of the spool directly or via a drive belt causing the carrier to advance. The device may also include means for tensioning or otherwise 15 maintaining the exposed area of the carrier within the chamber during inhalation by the patient.

The elongate carrier may be advanced into the chamber prior to inhalation by the patient preferably or the carrier may be advanced into the aerosolisation 20 chamber during inhalation to protect the powdered medicament from premature exposure. For example in one embodiment of the inhaler an unexposed area of carrier is rapidly advanced into the chamber upon actuation, and is rapidly decelerated or brought to an abrupt halt and 25 preferably is impacted thereby imparting sufficient energy to the medicament particles to effect their displacement from the carrier into the air stream.

In the preferred embodiment of the invention the elongate carrier is stored in a cassette both before and 30 after exposure. The cassette may comprise one or preferably two spools together with idlers or other rollers and include an exposure frame positioned within the chamber, through which the carrier is advanced. The cassette may be removable to allow the device to be 35 recharged with a new cassette. However, it is not essential for the exposed areas of the carrier to be retained within the device and spent carrier may be

advanced to the exterior of the device through a slot in the housing whereupon disposal may be effected by the patient, optionally with the aid of a cutting edge. This 5 arrangement is particularly suitable for a tape carrier which has transverse perforations to facilitate tearing off spent carrier.

The device preferably additionally comprises means for releasing medicament of respirable size from the 10 exposed area of carrier independent of the patients' inspiratory effort. The medicament release means overcomes the binding of the medicament particles to the carrier by mechanical effort e.g. impaction, vibrations, gas flow etc. or electrostatically. Mechanical energy 15 input may be achieved by:

impaction means e.g. one or more spring biased striking hammers having one or more impactions upon the exposed section of carrier;

brushing or scraping means having rotary or 20 reciprocal motion upon the exposed section of carrier e.g. spring charged or electrically driven rotary elements having projecting bristles or flaps; dragging the carrier across irregularities such as a serrated idler wheel or a surface bearing a plurality of embossed 25 structures or similar surface features;

pressurized gas flowing past, through or impinging upon the carrier, emanating from some compressed or liquefied gas supply;

vibration means for imparting vibration to the 30 exposed section of carrier, generally in the frequency range 5 to 50,000 Hertz; the vibrations may be derived electrically or piezoelectrically e.g. using the piezoelectrical properties of polymer PVDF₂; electromagnetically e.g. use of an electromagnetic 35 vibrating arm or pin; or mechanically e.g. use of rotating cams or serrated wheels, which may involve rapid revolution of the cam or wheel in contact with the carrier or movement of the carrier across the cam or wheel.

In a further embodiment vibration means may comprise means for the rapid acceleration of the elongate carrier, preferably from an unexposed storage state, into the

- 5 chamber followed by a sudden and rapid deceleration preferably to a dead stop to facilitate medicament release. In such an arrangement the particles of medicament are given sufficient kinetic energy such that they are released from the carrier when the carrier comes
- 10 to a rapid halt. In a further embodiment the elongate carrier is maintained as a slackened loop following advancement into the chamber. Upon actuation tensioning means effect a sudden and rapid straightening of the carrier loop causing particles of medicament to be
- 15 displaced. The loop may be positioned in any orientation relative to the patient port but in a preferred embodiment the centre of curvature of the loop is positioned between the carrier and patient port so that the particles of medicament are released towards the
- 20 patient port when the loop is rapidly straightened.

Medicament release efficiency may be increased when the carrier and/or the medicament particles have an intentional charge by reversing the polarity of the carrier at aerosolisation and inhalation.

- 25 The means for releasing medicament from the carrier during inhalation is preferably triggered in response to the patient inhaling in order to avoid the patient having to synchronise inhalation and actuation of the release mechanism. Airflow detection may conveniently be
- 30 accomplished by means of a movable vane positioned within the chamber or patient port, motion of the vane causing actuation of the release mechanism. Such a vane may also be constructed to prevent a patient exhaling through the device and/or preventing exhaled air from reaching the
- 35 stored carrier thereby avoiding any problems associated with moisture. Other such sealing means may also be employed. A suitable desiccant cartridge may be incorporated into the inhaler or may be incorporated into the carrier cassette.

Suitable medicaments for use in the invention include any drug or drugs which may be administered by inhalation which is a solid or may be incorporated in a 5 solid carrier. Suitable drugs include those for the treatment of respiratory disorders e.g. bronchodilators, corticosteroids and drugs for the prophylaxis of asthma. Other drugs such as anorectics, anti-depressants, anti-hypertensive agents, anti-neoplastic agents, anti- 10 cholinergic agents, dopaminergic agents, narcotic analgesics, beta-adrenergic blocking agents, prostoglandins, sympathomimetics, tranquillisers, steroids, proteins, peptides, vitamins and sex hormones may be employed.

15 Exemplary drugs include:

Salbutamol, Terbutaline, Rimiterol, Fenoterol, Pirbuterol, Reproterol, Adrenaline, Isoprenaline, Ociprenaline, Ipratropium, Beclomethasone, Betamethasone, Budesonide, Disodium Cromoglycate, Nedocromil Sodium, 20 Ergotamine, Salmeterol, Fluticasone, Formoterol, Insulin, Atropine, Prednisolone, Benzphetamine, Chlorphentermine, Amitriptyline, Imipramine, Clonidine, Actinomycin C, Bromocriptine, Buprenorphine, Propranolol, Lacicortone, Hydrocortisone, Fluocinolone, Triamcinolone, Dinoprost, 25 Xylometazoline, Diazepam, Lorazepam, Folic acid, Nicotinamide, Clenbuterol, Bitolterol, Ethinyloestradiol, Levonorgestrel and pharmaceutically acceptable salts thereof.

The powdered medicament may be finely micronised by 30 repeated step wise millings or a closed loop milling system and preferably is in the particle size range of 1 to 10 µm. The medicament may comprise one or more drugs, having one or more particulate forms and may include one or more physiologically acceptable or inert excipients. 35 The medicament particles may possess a coating comprising a surfactant, such as a perfluorinated surfactant or other surfactants such as Span 85, oleic acid, lecithins.

The predetermined area of carrier to be exposed in the chamber may be from 0.1 to 20 cm² and preferably from 1 to 5 cm² e.g. 2 to 3 cm². The medicament may coat one or more surfaces of the carrier and/or be entrapped within recesses or interstices in the carrier to allow a dose of 5 µg to 1 mg to be entrained within the airflow produced at inhalation. It is not essential that all of the drug be entrained within the airflow providing the amount of drug released from the predetermined area is substantially reproducible when the device is used.

The device of the invention may incorporate means to indicate one or more of a variety of parameters, such as, readiness for use, contents remaining, type of drug etc.

The indicator may just provide warning of the near-exhaustion of the medicament supply or may provide more detailed information, such as the sequential number of the dose or the number of doses left. The indicator may provide information of the date of manufacture or date of expiry of the medicament, as additional examples. For treatment intended to be taken regularly at set times, the indicator may display the intended day, date and time of administration. The information displayed by the indicator may conveniently be marked on the tape or tape covering by any appropriate method, whether involving printing, indenting etc. The area of tape in the indicator need not be that used to release the drug at that time. The indicator may be of an extremely simple form, such as a window or aperture to reveal the amount of elongate carrier remaining on the supply spool of a cassette, the window being visible externally or when a cover is opened to expose the cassette within the device.

The device may incorporate means to vary the area of elongate carrier exposed in the chamber thereby providing a variable dose facility. For example, an internal cover for the elongate carrier may be provided which is movable to expose varying lengths of carrier to the chamber. Alternatively, or additionally, rollers supporting the exposed length of the carrier may be movable to vary the

distance between the rollers thereby altering the exposed length of the carrier.

The devices of the invention may possess numerous advantages over the prior art devices. For example:

5 1. An inhaler with dosage control by the removal of powder from a fixed area of uniformly coated tape may show improved dose uniformity and respirable fraction uniformity over prior art devices. High respirable fractions are desirable because they allow a high
10 proportion of the drug to be inhaled into the lungs to provide therapeutic benefit, and reduce the proportion of the drug causing unwanted systemic side-effects following swallowing from the mouth and throat region.

15 2. The inhaler allows the accurate administration of smaller quantities of undiluted potent drugs (typically below 200 µg) such as corticosteroids, than is currently possible. This removes the problems associated with the use of excipients.

20 3. The storage of pure, powdered medicament on the surface of a tape lends itself to dosage adjustment or the use of different drugs with the minimum of effort and without reformulation work.

25 4. The inhaler is suitable for use with a wide variety of different medicaments.

5. By controlling the tape or web dimensions, a precise number of doses for inhalation can be stored in the inhaler.

30 6. The tape can be marked to allow the inhaler to register the exact number of doses remaining, or alternatively some counter mechanism can be driven by the carrier advance mechanism.

35 7. If indirect breath actuation is incorporated the amount of drug inhaled and the degree of particle deagglomeration are independent of the patient's inspiratory effort in the inhaler. Indirect breath-actuation can be used in this invention, offering the advantage for such devices of being able to overcome patients' hand/lung co-ordination problems, while at the same time providing a consistent dose each time for all

patients, irrespective of lung function.

8. If indirect breath actuation is incorporated the deagglomeration of the drug is not dependant on air flow rate, so that patients can be taught to inhale slowly
5 (unlike for most dry powder inhalers), thus reducing unwanted drug impaction on the back of their throats.

The invention will now be described with reference to the accompanying drawings in which:

Figure 1a is a section through an inhaler of the
10 present invention having a single integral carrier storage spool,

Figure 1b is a section through a disposable cassette for an inhaler of the present invention comprising a single carrier storage spool,

15 Figure 2 is a section through an inhaler of the present invention having a carrier of cord stored as a coil and integral take-up spool,

Figure 3 is a section through an inhaler of the present invention having a cassette comprising spooled
20 carrier storage and take-up means and impaction means for aerosolisation,

Figure 4 is a section through an inhaler of the present invention having concertina folded carrier storage and integral take-up spool,

25 Figure 5 is a section through a variant of the dry powder inhaler of Figure 4 having hybrid folded storage in addition to concertinaed stacking of carrier,

Figures 6a to 6d illustrate an inhaler of the present invention having indirect breath actuation,
30 prevention of through exhalation vane and impaction means for aerosolisation. Figure 6a is a front view, Figure 6b a rear view and Figure 6c a ventral view of the device exterior. Figure 6d is a transverse section through the inhaler along the axis A-A,

35 Figures 7a to 7c illustrate an inhaler of the present invention having manual actuation of impaction means for aerosolisation. Figure 7a is a front view and Figure 7b a rear view of the device exterior. Figure 7c is a transverse section through the inhaler along the

axis B-B,

Figure 8a is a section through an inhaler of the present invention having a revolving brush for aerosolisation of carrier borne medicament,

5 Figure 8b is a transverse section of the inhaler in Figure 8a along the axis C-C,

Figure 8c is a transverse section through a variation of the inhaler illustrated in Figure 8a having indirect breath actuation,

10 Figure 9 is a section through an inhaler of the present invention having a cassette comprising spooled carrier storage and take-up means, a recessed wheel driving a gear train for dose advancement and an electromagnetic vibrator,

15 Figure 10 is a section through an inhaler of the present invention having a carrier comprising a sheaf of sheets,

Figures 11a to 11c illustrate an inhaler of the present invention, having indirect breath actuation of 20 scraping means for medicament aerosolisation and a housing assembly having a cover. Figure 11a is a section through the device in closed format; Figure 11b is a section through breath actuation means at patient inhalation and Figure 11c is a section through the device 25 in open format at medicament aerosolisation,

Figures 12 and 12b illustrate sections through alternative inhalers of the present invention,

Figures 13 to 29 represent cross-sections through a further device in accordance with the invention,

30 Figures 30 and 31 represent cassettes containing elongate carrier in accordance with the invention, and,

Figures 32 to 35 represent cross-sections through devices in accordance with the invention adapted to contain the cassettes of Figure 30 or Figure 31.

35 Referring to Figure 1a, an inhaler of fully disposable format is illustrated, comprising a housing (1) having integral air vents (2) and defining an aerosolisation chamber (3) in communication with a patient port (4), having a mouthpiece adaptor (5) in this

embodiment. Alternatively, the device may be fitted with a nasal adaptor (not shown) or the device may be supplied with both. Within said chamber are integral carrier storage spool (6) and carrier engaging rollers 5 (48) which may be sprocketed to engage the carrier by means of a series of apertures cut in the carrier.

Carrier (8) is sequentially advanced across the exposure frame (9) and subsequent to exposure, through slot (49) in the housing. Spent carrier may be discarded 10 by the patient with the aid of cutting edge (50) in a process analogous to a cap gun or a tape dispenser. Dose advancement means are not shown but may comprise 15 mounting rollers (48) on a drive shaft extending through the housing (1). This may be manually turned with the aid of a knurled knob. Alternatively a suitable gear train may be connected to roller(s) (48) and a recessed dose advancement lever or wheel mounted in the housing to effect dose advancement.

Figure 1b is a section through a cassette of 20 preloaded carrier comprising: a cassette housing (16), a carrier storage spool (17) and free carrier leader portion (18) which is inserted into a device take-up means. Such a cassette is suitable for use in the inhaler of Figure 1a (optionally as a re-usable device, 25 where the cassette replaces spool (6)). The leader portion upon loading would be threaded, in a manner analogous to loading a 35mm photographic film to engage rollers (48) and protrude through slot (49). Alternatively the leader portion may be inserted into a 30 take-up spool by means of a slot cut in said spool.

Referring to Figure 2, an inhaler of fully disposable format is illustrated, comprising a cord carrier (26) stored as a coil (27) in a storage compartment (28) distinct from aerosolisation chamber 35 (3). Means for sealing stored cord from moisture ingress may be provided at opening (52). Sequential advancement of cord under tension by sprung rollers (24) to exposure frame (9) allows for aerosolisation of the medicament carried. Subsequent to exposure, spent carrier (29) is

taken up by integral spool (7). Dose advancement means are not shown but may comprise a shaft continuous with the spindle of spool (7) extending through the housing and turned by means of a knurled knob, or by a suitable 5 gear train engaging spool (7) and connected to a recessed dose advancement wheel or lever mounted in the housing.

Referring to Figure 3, an inhaler of re-usable format is illustrated comprising a disposable cassette (10) having carrier storage spool (11) and take-up spool 10 (12). Spools (11,12) are engaged respectively on cassette insertion by spindles (11a,12a). The embodiment depicted comprises impaction means (13) for the aerosolisation of medicament at exposure frame (9) upon release, either manually or indirectly by breath 15 actuation means, explained hereinafter, of a spring biased hammer (14) held in an armed position (as illustrated) by catch (15). Means for arming the hammer are not shown.

An inhaler of fully disposable format is produced by 20 replacing cassette (10) with integral spools (6) and (7).

Referring to Figure 4, an inhaler having folding means of carrier storage is illustrated, comprising a carrier storage compartment (22), wherein carrier (8) is stored in a concertinaed configuration (23) such that 25 medicament bearing surfaces are in association. Carrier is sequentially advanced under tension by rollers (53) which may be spring biased or sprocketed to engage the carrier in register and provide support means. Spent carrier exposed at exposure frame (9) is taken up by 30 integral spool (7) which interacts with dose advancement means.

Referring to Figure 5, a variant of the inhaler depicted in Figure 4, comprising carrier (8) being folded across the longitudinal axis prior to concertina folding 5 (23). Medicament bearing surfaces of the carrier are folded inwardly to prevent net medicament transfer and to reduce moisture ingress. Sequential advancement of carrier, by drive means associated with integral take-up spool (7) and under tension provided by roller (53), 10 causes unfolding of carrier immediately prior to exposure at exposure frame (9). Mouthpiece (5) is depicted with dotted lines to illustrate positioning.

Referring to Figure 6a, a front view of an inhaler having indirect breath actuation of impaction means is 15 illustrated. Vane (56), explained hereinafter is shown in the displaced position. Exposure frame (9) presented to the patient by insertion of mouthpiece (5) into the buccal cavity defines the exposed area of carrier (8). Striking hammer (14) is held in an armed position by 20 catch (15) and is released by the detection of an air flow through the device.

Figure 6b depicts a rear view of the inhaler of Figure 6a and illustrates the position of air vents (2), striking hammer arming rod (54) and dose advancement 25 lever (40) recessed in slot (55).

Figure 6c depicts a ventral view of the inhaler of Figure 6a and serves to illustrate the housing extension (58) containing indirect breath actuation means and the arming rod (54) in non-armed position flush with the 30 housing.

Figure 6d depicts a section through the inhaler along the axis A-A. The inhaler comprises: a housing (1) having an extension (58), for purposes of indirect breath actuation with integral air vents (2), said housing 35 defining an aerosolisation chamber (3) in communication with patient port (4) and air vents (2). Carrier (8) is taken up by spool (7). Carrier storage means are not shown but typically would be a spool.

Unexposed carrier (8) is sequentially advanced across exposure frame (9) by recessed lever (40) driving a suitable gear train (41) turning spool (7). Striking 5 hammer (14) is primed by the patient immediately prior to inhalation by retracting spring biased rod (54) until catch (15) is engaged.

Vane (47) is capable of being displaced when an air flow is generated by patient inhalation through the 10 device. The vane is spring biased (not shown) to return to the displaceable home position when the air flow is halted. Displacement of the vane (47) produces an interaction with catch (15) to release the striking hammer (14). Impaction of the hammer with carrier (8) 15 releases medicament particles of respirable size into aerosolisation chamber (3), whereupon they are entrained into the developing air stream as the patient inspires.

Vane (56) ensures unidirectional flow of air from the exterior atmosphere, via air vents (2) to patient 20 port (4), by being displaceable in the forward direction only. Movement in the reverse direction upon patient exhalation is prevented by stop (57).

In a modification (not shown) the vanes (47) and (56) may be replaced by a simple vane.

Referring to Figures 7a to 7c, an inhaler having a cord carrier and manually circulated impaction means for aerosolisation. Cord (27) is sequentially advanced across exposure frame (9). Rod (54) is retracted immediately prior to use until the hammer (14) engages 25 catch (15). The patient inserts the inhaler into his oral or nasal cavity and depresses button (44) which connects with spring biased lever (46) to cause catch (15) to release the armed striking hammer. The hammer contacts the cord with sufficient energy input to aerosolise 30 medicament particles of respirable size. Simultaneously inspiration produces an air flow through the device 35 entraining aerosolised medicament to the patient.

Referring to Figures 8a to 8c, an inhaler of fully disposable format having both integral spooled carrier storage (6) and take-up (7) and brushing/scraping means for aerosolisation. Carrier (8) is sequentially advanced across the carrier support (42) in contact with a spring powered or electrically driven (not shown) rotary brush (43). Contact is only made between brush filaments and carrier at the exposure frame (9). Synchronisation of brush action with exposure of a fresh section of tape is achieved by the embodiment illustrated by Figures 8a and 8b in which a push button (44) interacts with a spring biased check pawl (45) to prevent advancement of carrier by a recessed lever (40) and suitable gear train (41) until the button is depressed. The same push button or a different push button switch when depressed may complete a circuit comprising a battery and a motor (not shown) or allow a tensioned spring mechanism (not shown) to revolve the brush. Alternatively the gear train (41) responsible for carrier advancement may interact with the brush directly, thereby synchronising their motion.

Figure 8c illustrates the application of indirect breath actuation to a further embodiment of the device whereby a vane (47) movably displaced by a developing air stream during patient inspiration, completes an electrical circuit containing a battery and a motor driving rotary brushing (43).

Figure 9 illustrates an inhaler of re-usable format with part of the housing and disposable cassette (10) cut away. The cut away illustrates the relative position of carrier storage spool (11) and carrier take-up spool (12) within said cassette to the gear train (41). Sequential advancement of fresh carrier (8) to exposure frame (9) is completed by a recessed dose advance wheel (38) engaging gear train (41) and revolving take-up spool (12). Electromagnetic vibrator (37) is activated by completion of a circuit containing a battery cell. This may be achieved by a push button or the action of a displaceable vane (not shown) as described in Figures 8a to 8c.

Vibrating head (60) contacting the carrier at the exposure frame causes the release of medicament into chamber (3) where it may be entrained by the patients inspiratory efforts.

5 Referring to Figure 10, a section through an inhaler of fully disposable format comprising sheets of carrier (30) stored as a sheaf (31) in a storage compartment (32). The sheaf is supported by a spring biased plate (33) such that individual sheets can be advanced by means
10 of rollers (34) which may be sprocketed engaging carrier sheets with suitable apertures in register to an exposure frame (9) prior to aerosolisation. Spent carrier sheets are ejected by rollers (34) through a slot (35) in the housing (1) for disposal by the user.

15 Figures 11a to 11c illustrate sections through an inhaler (75) having a housing (76) comprising casing (78) and a cover (77) pivotally mounted at (79) movable between a closed format shown in Figure 11a and an open format shown in Figure 11c. The inhaler is maintained
20 in a closed position whilst not in use providing a compact, convenient shape minimising contamination from dirt, moisture ingress etc.

The housing has one or more integral air vents (2a), which are exposed when the device is in the open format,
25 and defines an aerosolisation chamber (3) in communication with a patient port (4), having a mouthpiece adaptor (5). Within the chamber are integral carrier storage spool (6), idler (81) having four lobed catches (86) of equal dimension, and carrier take-up
30 spool (7) having a pawl (82) and ratchet (83) allowing unidirectional rotation of the spool (indicated by the arrow of Figure 11c).

The device is cocked for use by fully opening the cover (77) causing tensioning of the device spring (89)
35 which acts on drive peg (84) which is engaged in a slot (90) in carrier take-up spool (7). Rotation of take-up

spool (7) by the drive peg (84) is prevented by the engagement of displaceable idler catch (86) with vane pivot axle (85a). Opening the device exposes the 5 patient port and mouthpiece adaptor to the patient.

Figure 11b illustrates the actuation of the device by a developing airstream as the patient inhales. Vane (85) provides indirect breath actuation means and may additionally prevent through device exhalation by the 10 patient. The vane is pivoted so as to be displaceable when an airflow is generated through the device from the exterior via vents (2a) to the patient port (4).

Unidirectional displacement of vane (85) is provided by the vane engaging stop (57). The vane may have a width 15 equal to the patient port such that upon exhalation the vane sealingly contacts stop (57) preventing the ingress of moist, exhaled air. In the home (non-displaced) position the vane engages catch (86) preventing carrier uptake. Inhalation displaces vane (85) into recess (91) 20 whilst displacing and freeing idler catch (86) from engagement by vane pivot axle (85a) and allowing idler (81) to complete the cycle until the following catch (86a) re-engages the vane pivot axle. The curvature of each catch aids the stepwise engagement of vane pivot 25 axle (85a) to define dosage lengths of carrier.

Referring to Figure 11c, medicament is removed from the carrier by a combination of the patient's inspiratory effort, acceleration/deceleration impaction and the action of scraper (87). With idler (81) free from 30 interruption the tensioned spool (7) rapidly winds up carrier (8) under the influence of drive spring (89) moving drive peg (84) until the passage of idler (81) is abruptly halted by the next catch (86a) re-engaging pivot axle (85a). The resulting momentum of medicament 35 particles, the impaction due to the arresting of carrier velocity and the resulting vibration of the carrier aid medicament removal. The curvature of idler (81) bends the carrier with drug coating outwards as each new

unexposed section is indexed onto the idler (81) and exposed to the airstream, thereby easing the release of powder. Scraper (87) aids the release of medicament by 5 contacting the exposed area of carrier prior to take-up and mechanically displaces the medicament particles. After use the device is returned to the closed format by the patient, the drive peg (84) being returned to its original position under the influence of return spring 10 (80).

Figure 12a and 12b illustrate alternative embodiments of a variation of the inhaler illustrated in Figures 11a to 11c. Both devices are shown in the inactive closed format.

15 Figure 12a illustrates an inhaler (93) having a spring biased cam follower comprising a spring (95), biasing wheel mounting (96) and bearing cam follower wheel (97). Cam follower wheel (97) engages and travels the surface of cam (98) during cam rotation. Cam (98) 20 has an essentially square cross section and abuts idler (99) having four displaceable catches (100) of equal dimensions. Vane (85) provides indirect breath actuation means and may form a one way valve preventing exhalation through the inhaler. The device is cocked as described 25 previously for Figures 11a to 11c, movement of the carrier being prevented by engagement of catch (100) with vane pivot axle (85a).

When the patient inhales, vane (85) is displaced into recess (91). Idler (99) is no longer blocked 30 allowing carrier (8) to be drawn onto take-up spool (7). As the carrier is taken up, passage of cam follower wheel on the surface of cam (98) for the first 45° of rotation compresses spring (95) such that during the second part 35 of the cycle (a further 45° rotation), cam follower wheel (97) causes the cam to rotate faster than take-up spool (7). A loop of carrier (not shown) develops until idler (99) rotation is prevented by engagement of following

catch (100a) with vane pivot axle (85a). Subsequently the loop of carrier is snapped tight by take-up spool (7) causing release of medicament into the airstream.

5 Figure 12b illustrates an inhaler (105) having a cam assembly comprising a central cam (107) of essentially square cross section abutting a guide wheel (108) bearing carrier (8) and an interrupter wheel (109) having, at the four compass positions, circular elements (110) of equal
10 dimensions and freely rotatable about axis; a spring biased cam follower comprising a spring (95) biasing wheel mounting (96), supporting cam follower wheel (97) and an interrupter assembly comprising a rocker arm (112) pivoting about pivot point (112a) and bearing a peg (114)
15 and a catch (115) having a spring leaf (116). Catch (115) is able to pivot about pivot point (113). Cam follower wheel (97) engages and travels the surface of central cam (107) during rotation of the cam assembly. Rocker arm (112) is biased by the action of a weak spring
20 (117), fixed between peg (118) of housing (1) and slot (119), such that the rocker arm nose (112b) stepwise engages circular elements (110) at every 90° rotation of the cam assembly.

The device depicted illustrates alternative
25 embodiments to the format of the drive (89) and return (80) springs described previously and the idler/ratchet mechanism ensuring unidirectional rotation of carrier take-up spool (7).

In use, the device is cocked as described for
30 Figures 11a, 11c and 12a by opening of the cover, whereby drive peg (84) is tensioned by the activity of drive spring (89a). Unidirectional (clockwise) rotation of take-up spool (7) is effected by the action of spindle (121) having a series of stepped projections (121a)
35 engaging the spring leaves (122) of the spool in the reverse (anti-clockwise) direction. Tensioned drive peg (84) imparts a slight rotation to take-up spool (7)

causing tightening of any slack carrier (8). Rotation of the take-up spool (7) is prevented by the engagement of rocker arm (112) to the interrupter wheel (109), but 5 the rocker nose (112b) is caused to be displaced slightly on the circular element (110a). The slight lift imparted to the rocker nose (112b) in a reciprocal motion about the pivot causes catch (115) to engage the curved surface (123). The curved surface (123) directs catch (115) to 10 rest upon vane (85). Vane (85) provides indirect breath actuation.

Patient inhalation through mouthpiece adaptor (5) displaces vane (85) into recess (91) as described previously. Rotation of the vane about pivot point (124) 15 causes the displacement of catch (115). As catch (115) is displaced from a blocking to a non-blocking position, rocker arm (112) is lifted by interrupter element (110a) thus allowing rotation of cam assembly. Rocker arm (112) is maintained in contact with surface of interrupter 20 wheel (109) by spring (117) so that it contacts the following interrupter element (110b). This provides a stepwise mechanism (every .90° rotation of the cam assembly) for carrier exposure. Co-operation of central cam (107) and spring biased cam follower cause a loop of 25 carrier to be formed which is snapped tight causing release of medicament particles as described in Figure 12a.

Figures 13 and 14 represent a cross-section through a further inhalation device in accordance with the 30 invention showing the device with the cover closed for storage and with the cover open in the dispensing position respectively.

The device comprises a housing (200) defining a chamber (202) in communication with a mouthpiece (204). 35 A cover (206) is pivotable about pivot point (208) between a closed position as showed in Figure 13 in which the contents of the device are protected against ingress of moisture and contaminants, and a dispensing position, ready for patient's use, as shown in Figure 14.

The housing (200) contains an elongate carrier bearing powdered medicament which is held within a removable cassette shown in dotted outline at (210). The 5 cassette comprises a supply spool (212) which initially holds the bulk of the elongate carrier wound in the form of a roll. From the supply spool the elongate carrier passes round an idler roller (214) and a spiked control roller (216) to a take-up spool (218). An area of the 10 elongate carrier between the idler roller (214) and the spiked control roller (216) is exposed to the chamber (202); when the device is actuated powdered medicament from this exposed area is released from the elongate carrier and entrained in the patient's airflow through 15 the chamber.

The device is very simple to operate requiring only that the patient opens the cover (202) and inhales through the mouthpiece (204). This action activates a fairly complex sequence of operation of four separate 20 mechanisms. These mechanisms comprise a driving mechanism for advancing the elongate carrier, driven by a spring which is cocked by opening the cover; a trigger mechanism which ensures the energy stored in cocked drive spring is not released until inhalation is sensed, an 25 impaction mechanism which causes the exposed area of the elongate carrier to be impacted ensuring release of medicament into the air stream and a braking mechanism which holds the elongate carrier taut while the impaction takes place. For ease of comprehension the 30 components and action of the individual mechanisms will be described separately.

Figures 15 to 17 illustrate the drive mechanism for advancement of the elongate carrier. The drive mechanism comprises a drive spring (220) positioned between the 35 drive gear (222) and the portion (224) of the cover (206); when the cover (206) is closed over the mouthpiece it is lightly held shut by the action of the drive spring.

Figures 15a, 15b and 15c, represent cross-sections at different heights through the drive arrangement generally shown within the circle (I) for the take-up 5 spool (218) of the cassette (210) (shown in Figures 13 and 14). The drive from the take-up spool pinion (226) is transmitted via a spring (228) and ratchet arrangement comprising a ratchet gear (230) and ratchet pawl (232) to a spool-driving peg (234) which engages 10 with the take-up spool of the cassette. The spring (228) allows the drive gear to move the pinion through a greater angle of rotation than the elongate carrier allows the spool to move. The ratchet arrangement allows the drive gear to be reset without unwinding the tape 15 from the take-up spool.

Figures 15d and 15e represent cross-sections at different heights within the circle (II) and illustrate how the drive from the control roller pinion (236) is transmitted via a ratchet mechanism comprising a ratchet 20 gear (238) and a pawl (240) mounted on the control roller pinion so that the mechanism may be reset without moving the control roller and elongate carrier. The casing of the ratchet gear (238) is in the form of an escape wheel having stops (242) which interact with the triggering 25 mechanism to limit the movement to one revolution per cycle. The drive from the control roller pinion is finally transmitted to the control roller via a drive spigot (244).

Figure 16 shows the cover (206) opened to expose the 30 mouthpiece and to cock the drive or advancement mechanism by applying pressure to the drive spring (220) caused by movement of the portion (224) of the cover when the cover is pivoted about its pivot point. Although the drive spring (220) is loaded the drive gear and associated 35 pinions cannot move as the control idler is locked by the escapement (242) (Figures 15d and 15e).

When the escapement releases the control idler, movement of the drive gear (222) and associated pinions (226 and 236) is effected under the influence of the 5 drive spring (220), the direction of movement of the components being shown by the arrows on Figure 17.

After actuation of the device, when the cover is closed as shown in Figure 18, a step (244) on the cover (206) engages a spigot (246) on the drive gear (222) 10 returning the drive mechanism to its initial position and causing rotation of the pinions (226 and 236) as shown by the arrows in Figure 18.

The components and mode of action of the breath actuated triggering mechanism is depicted in Figures 19 15 to 23.

In addition to the escape wheel comprising stops (242) on the control idler shaft, the triggering mechanism comprises a pivoting vane (248) which is capable of pivotal movement about pivot point (250), and 20 an escapement lever (252) which is pivoted about pivot point (254). When the vane is closed and abuts stop (256) the step (258) on the escapement lever abuts stop (242) on the escape wheel. Pivotal movement of the escapement lever (252) is prevented by engagement of a 25 projection (260) on the escapement lever with a curved abutment surface (262) formed near the pivot point (250) of the vane. When the cover is opened as shown in Figure 20, the drive spring (220) is tensioned but movement of the drive gear (222) and the control roller (236) in the 30 direction of the arrows is prevented by the escapement wheel. When the patient breathes through the mouthpiece the vane (248) is lifted by the airflow as shown in Figure 21. Movement of the vane (248) allows pivotal movement of the escapement lever (252) moving the step 35 (258) on the escapement lever away from the stop (242) on the escapement wheel thereby allowing rotation of the control roller pinion (236), the gear train (222) and the

take-up spool pinion (226). Rotation of the pinions (226 and 236) causes rotation of their associated spigots (234 and 244) thereby rotating the take-up spool (218)

- 5 and control roller (216) of the cassette (210).

When the control roller (216) has completed almost one revolution, a second stop (242) on the escape wheel contacts step (262) of the escapement lever (252) (Figure 22) and the control roller and hence the elongate carrier

- 10 are arrested.

After the device has been used and the cover (206) is closed the vane pivots back to its closed position and the escapement lever (252) is pushed up to release the engagement between the step (262) and the escapement

- 15 wheel and step (258) on the escapement lever (252) engages the stop (242). The movement of the various components is depicted in Figure 23 by the arrows.

The device comprises means to facilitate release of the powdered medicament from the elongate carrier in the

- 20 form of an impaction mechanism which is depicted in Figures 24 to 26. After the patient has begun to breathe through the mouthpiece releasing the triggering

mechanism, and the elongate carrier has been advanced by the drive mechanism, the area of the carrier exposed to

- 25 the chamber is struck by an impactor arm driven by a powerful spring to release medicament from the elongate carrier into the air stream.

Figure 24 shows the impactor mechanism comprising an impactor arm (264) which is pivotally mounted about pivot

- 30 point (266) and has an impaction head (268) which strikes the elongate carrier (not shown). The impactor arm is biased by spring (270). The impactor arm is held clear of the elongate carrier by a catch (272) which engages the impaction head (268) until the triggering mechanism

35 is activated. When the triggering mechanism has activated the drive mechanism and the escapement wheel rotates, one of the stops (242) acts as a cam to push the

catch (272) against its integral spring (274) and releases the impaction head thereby allowing pivotal movement of the impaction arm under the influence of the 5 spring (270) so that the impaction head strikes the exposed area of the elongate carrier (not shown). The direction of movement of the catch (272) and the impaction head (268) is shown by the arrows in Figure 25.

Figure 26 shows the impaction device being reset 10 during closing of the cover (206). Cam surface (276) is provided on the cover which bears against the impactor arm turning it to its original position and compressing spring (270). During this movement the impaction head slides up catch (272) initially moving the catch back 15 against its integral spring (274) until the impaction head is clear of the stop (278) of the catch and thereafter the catch moves to its blocking position engaging the impaction head under the influence of its integral spring (274).

20 In order to ensure efficient release of powdered medicament from the elongate carrier it is necessary that the exposed area of the elongate carrier is held taut while being struck by the impactor head. The control roller and take-up spool prevent the elongate carrier 25 from retreating by virtue of the ratchet arrangements described with reference to Figures 15b and 15d. In order to prevent the carrier spool from unwinding during impaction, the carrier spool is arrested just prior to impaction by means of a pawl which engages a ratchet 30 wheel (282) attached to the carrier spool shaft.

Normally, the pawl (280) is held out of engagement with the ratchet (282) by contact with the impaction head (268) of the impactor arm (264) (Figure 27), but once the impactor arm moves towards the elongate carrier, the pawl 35 (280) springs into engagement with the ratchet (282) under the influence of spring (284) (Figure 28). This engagement prevents further rotation of the carrier spool thereby arresting the advancement of the elongate

carrier, securely holding the length of the elongate carrier between the carrier spool and control roller so that the impaction head strikes the taut elongate
5 carrier thereby imparting sufficient energy thereto to cause powdered medicament to be released into the air flow caused by the patient's inspiration through the mouthpiece.

During closing of the cover (206) movement of the
10 impactor arm resets the pawl (280) lifting it out of engagement with the ratchet (282) and compressing spring (284) (Figure 29).

Figures 30 and 31 represent alternative forms of cassettes containing an elongate carrier bearing powdered
15 medicament in accordance with the invention. Each cassette (210) comprising supply spool (212), an idler roll (214), a control roller (216) and a take-up spool (218). The elongate carrier passes from the supply spool around the idler and control rollers to the take-up
20 spool.

The cassettes of Figures 30 and 31 differ from that shown in Figures 13 and 14 in that they possess an integral drive belt (282). The purpose of the belt is to keep the rotational movement of the supply and take-up
25 spools in precisely the correct relationship to each other and to the control roller regardless of the proportion of elongate carrier that has been passed from one spool to another. This objective is achieved by the drive belt (282) being in frictional contact with the
30 control roller (216) (beneath the elongate carrier), and with the outside surface of the elongate carrier on each of the spools. In order to achieve the necessary arc of contact between the drive belt (282) and the elongate carrier on the spools, the cassette additionally
35 comprises rollers (284). The elongate carrier is advanced simply by driving the control roller (216) which causes the correct rotational movement of each spool. As

each spool is driven directly by the control roller (216), additional mechanisms to arrest the carrier spool and to wind the elongate carrier on to the take-up spool
5 are no longer required.

- Figures 32 to 35 illustrate an inhalation device in accordance with the invention suitable for use with the cassettes of Figures 30 and 31. The cassette of Figure 30 is shown in the device of Figures 34 and 35.
- 10 The cocking, triggering and impaction mechanism of the inhalation device is shown in Figures 32 and 33 and these mechanisms have substantially identical components and modes of action to those shown in Figures 13 to 29. Like parts are indicated by like reference numerals.
- 15 Figure 34 shows the cassette (210) mounted in the device with the cover (206) closed and Figure 35 shows the device in use with the impaction head (268) striking the exposed area of the elongate carrier.

CLAIMS

1. A dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and an elongate carrier bearing a powdered medicament, the device being constructed and arranged such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that particles of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow.
5. 2. A device as claimed in Claim 1 comprising means to advance the elongate carrier to expose an area of said carrier within the chamber, said means being operable prior to or during patient inhalation through the patient port.
10. 3. A device as claimed in Claim 1 or Claim 2 comprising means for releasing medicament of respirable size from the exposed area of carrier.
15. 4. A device as claimed in Claim 3 in which the means for releasing medicament comprises electrical, piezo-electrical, electromagnetic or mechanical means for vibrating the exposed area of the carrier.
20. 5. A device as claimed in Claim 4 in which said means produces vibrations in the frequency range of from 5 to 50000Hz.
25. 6. A device as claimed in Claim 3 in which the means for releasing medicament comprises means for impacting or striking the exposed area of the carrier either singularly or by a plurality of such strikings or impactions.




7. A device as claimed in any one of Claims 3 to 6 comprising means to hold the elongate carrier taut during vibration or impaction.
- 5 8. A device as claimed in Claim 3 in which the means for releasing medicament comprises means for brushing or scraping the exposed area of the carrier by rotary or reciprocal motion or means for dragging the carrier across a surface having irregularities, or means having
- 10 10. an edge or corner having a small radius of curvature arranged such that the exposed surface of the elongate carrier is given a sharp convex curvature.
9. A device as claimed in Claim 3 in which the means for releasing medicament causes an unexposed area of
- 15 15. carrier to advance rapidly into the chamber and come to an abrupt halt causing medicament release, or causes a length of the carrier to take the form of a slackened loop which is rapidly straightened causing medicament release.
- 20 10. 10. A device as claimed in Claim 3 in which the means for releasing medicament comprises a source of a compressed or liquefied gas.
11. A device as claimed in any one of Claims 3 to 10 in which the means for releasing medicament is actuated by
- 25 25. inhalation at the patient port.
12. A device as claimed in Claim 11 comprising a moveable vane for triggering the means for releasing medicament, the vane being movable upon inhalation through the patient port.
- 30 13. A device as claimed in Claim 12 in which the vane acts as a one-way valve allowing passage of air from the chamber to the patient port but not from the patient port to the chamber.
14. A device as claimed in any one of Claims 2 to 13
- 35 35. comprising biasing means for operation of the means to advance the carrier and/or means for releasing medicament.

15. A device as claimed in Claim 14 additionally comprising a cover for the patient port which may be pivoted between open and closed positions, said biasing means being primed by opening said cover.
16. An elongate carrier comprising an elongate substrate releasably supporting particles of powdered medicament, at least a portion of the particles having a particle size in the range from 1 to 10 μm .
17. An elongate carrier as claimed in Claim 16 in which the substrate is in the form of a tape or web which is wound on a spool, wound in the form of a roll or folded into a concertina arrangement.
18. An elongate carrier as claimed in Claim 16 or Claim 17 which additionally comprises a backing layer comprising a metal foil, a polymeric material, a metallised polymeric material or paper.
19. An elongate carrier as claimed in any one of Claims 16 to 18 in which the carrier comprises polyethylene, polypropylene, polyester, polytetrafluoroethylene, a co-polymer thereof or cellulose.
20. An elongate carrier as claimed in any one of Claims 16 to 19 in which a surface of the substrate comprises:
 - (i) one or more grooves of width 10 to 500 μm at the carrier surface and depth 10 to 500 μm , the grooves containing particles of powdered medicament,
 - (ii) randomly orientated pores of diameter 0.1 to 100 μm , at least a portion of the pores being on the exterior surface and containing particles of powdered medicament,
 - (iii) apertures of diameter 1 to 100 μm in at least one surface produced by laser drilling, the apertures containing particles of powdered medicament, or,
 - (iv) an embossed surface.
21. An elongate carrier as claimed in any one of Claims 16 to 20 in which the substrate comprises woven or non-woven fibers having a diameter of from 0.1 to 100 μm .




22. An elongate carrier as claimed in any one of Claims 16 to 21 in which the medicament is selected from Salbutamol, Terbutaline, Rimiterol, Fenoterol,
- 5 Pirbuterol, Reoproterol, Adrenaline, Isoprenalin, Ociprenalin, Ipratropium, Beclomethasone, Betamethasone, Budesonide, Disodium Cromoglycate, Nedocromil Sodium, Ergotamine, Salmeterol, Fluticasone, Formoterol, Insulin, Atropine, Prednisolone,
- 10 Benzphetamine, Chlorphentermine, Amitriptyline, Imipramine, Clonidine, Actinomycin C, Bromocriptine, Buprenorphine, Propranolol, Lacicortone, Hydrocortisone, Fluocinolone, Triamcinolone, Dinoprost, Xylometazoline, Diazepam, Lorazepam, Folic acid, Nicotinamide,
- 15 Clenbuterol, Bitolterol, Ethinyloestradiol, Levonorgestrel and pharmaceutically acceptable salts thereof.
23. An elongate carrier as claimed in any one of Claims 16 to 22 in the form of a tape or web having a width of 20 from 0.5 to 3cm.
24. A cassette comprising a housing and an elongate carrier as claimed in any one of Claims 16 to 23.
25. A cassette as claimed in Claim 24 which comprises a pair of spools, the elongate carrier being wound on one 20 spool and extending to the second spool whereby advancement of the elongate carrier causes the elongate carrier to be unwound from the first spool and wound on the second spool.
26. A cassette as claimed in Claim 25 which additionally 30 comprises a drive belt in contact with elongate carrier wound on the spools such that movement of the drive belt causes advancement of the elongate carrier.
27. A device as claimed in any one of Claims 1 to 15 which comprises an elongate carrier or cassette as 35 claimed in any one of Claims 16 to 26.

28. A dry powder inhalation device comprising a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, and a plurality of carrier sheets each releasably bearing a powdered medicament, the device being constructed and arranged such that each carrier sheet may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to patient port through the chamber such that particles of the powdered medicament of respirable size from said exposed carrier are entrained within the air flow.
29. A dry powder inhalation device comprising a housing defining a chamber in communication with a patient port in the form of a mouthpiece or nasal adaptor, the device being constructed and arranged to accommodate an elongate carrier bearing a powdered medicament such that areas of predetermined size of the elongate carrier may sequentially be exposed within the chamber, the device comprising one or more air inlets such that when a patient inhales through the patient port an air flow is established from the air inlet(s) to the patient port through the chamber such that particles of the powdered medicament of respirable size from said exposed area of the elongate carrier are entrained within the air flow.

1/23



2/23

*Fig. 4.**Fig. 5.***SUBSTITUTE SHEET**




Fig. 6a.




Fig. 6b.




Fig. 6c.




Fig. 6d.

4/23

Fig.7a.




Fig. 7b.





Fig. 7c.



5/23

Fig. 8a.




Fig. 8b.





Fig. 8c.



6/23

Fig. 9.





Fig. 10.



7/23

Fig.11a.






Fig.11b.




8/23

Fig.11c.



9/23


Fig. 12a.





SUBSTITUTE SHEET

10/23

Fig.12b.




11/23



SUBSTITUTE SHEET

72/23



13/23

Fig.16.





Fig.17.



14/23

Fig. 18.





Fig. 19.

**SUBSTITUTE SHEET**

15/23

Fig. 20.





Fig. 21.

**SUBSTITUTE SHEET**

16/23

Fig.22.






Fig.23.



*17/23**Fig.24.*

18/23

Fig. 25.





Fig. 26.



79/23

Fig. 27.






Fig. 28.

**SUBSTITUTE SHEET**

20/23

Fig. 29.



SUBSTITUTE SHEET

21/23

Fig. 30.





Fig. 31.



22/23

Fig. 32.





Fig. 33.



23/23

Fig.34.





Fig.35.

**SUBSTITUTE SHEET**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 90/02412

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: A 61 M 15/00

II. FIELDS SEARCHED

Minimum Documentation Searched 7

Classification System	Classification Symbols
IPC⁵	A 61 M, A 61 K, A 61 B, B 65 D, A 61 J, A 61 L

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	FR, A, 2516387 (PIERRE FABRE S.A.) 20 May 1983 see page 1, line 20 - page 2, line 7; page 2, lines 22-30; page 6, lines 6-10; claims 1,2,4,7,10; figure 3	1-4,6,10- 12,14-16, 29
A	--	28
Y	DE, U, 8806288 (GLAXO INC.) 27 October 1988 see page 7, lines 1-2; page 14, line 26 - page 15, line 33; figures 1-3	1-4,6,10- 12,14-16, 29
A	EP, A, 0224335 (BIOTRACK INC.) 3 June 1987 see abstract; page 2, lines 21-27; figure 2	-- 1
A	DE, A, 2837040 (SIEMENS AG) 28 February 1980 see claim 1; figure 1	-- 1,4
A	GB, A, 2061735 (RIKER LABORATORIES INC.)	-- 1,14,15 . /,

* Special categories of cited documents: 10

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

6th August 1990

Date of Mailing of this International Search Report

26.08.90

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	20 May 1981 see abstract; page 6, lines 3-57; figures 5-7 --	
A	WO, A, 8501880 (RIKER LABORATORIES INC.) 9 May 1985 see abstract; page 10, line 21 - page 11, line 8; figures 11-15 --	1,11-15
A	DE, C, 25422 (HASSLER) 9 January 1884 see page 2, left-hand column, line 35 - right-hand column, line 7; figures 3,4 -----	8

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9002412
SA 36783

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 04/09/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR-A- 2516387	20-05-83	None		
DE-U- 8806288	15-09-88	AU-A- 1606088 DE-A- 3816276 FR-A- 2615106 GB-A- 2204799 JP-A- 1046471 NL-A- 8801239		17-11-88 24-11-88 18-11-88 23-11-88 20-02-89 01-12-88
EP-A- 0224335	03-06-87	US-A- 4712460 AU-B- 585668 AU-A- 6512186 JP-A- 62167568 US-A- 4797283		15-12-87 22-06-89 21-05-87 23-07-87 10-01-89
DE-A- 2837040	28-02-80	None		
GB-A- 2061735	20-05-81	AU-B- 545574 AU-A- 6396080 CH-A- 656311 EP-A, B 0028162 WO-A- 8101243 NL-T- 8020393 SE-A- 8104001 US-A- 4446862		18-07-85 22-05-81 30-06-86 06-05-81 14-05-81 01-09-81 26-06-81 08-05-84
WO-A- 8501880	09-05-85	AU-B- 578915 AU-A- 3558384 CA-A- 1236359 DE-A- 3470844 EP-A, B 0147028 JP-T- 61500254 US-A- 4664107		10-11-88 22-05-85 10-05-88 09-06-88 03-07-85 20-02-86 12-05-87
DE-C- 25422		None		